Immunomodulatory properties of multipotent adult progenitor cells and uses thereof

Patent metadata

Field	Value
Publication number	US-11197889-B2
Application number	US-201715804760-A
Country	US
Kind code	B2
Filing date	Nov 6, 2017
Priority date	Nov 9, 2005
Publication date	Dec 14, 2021
Grant date	Dec 14, 2021

Abstract

Isolated cells are described that are not embryonic stem cells, not embryonic germ cells, and not germ cells. The cells can differentiate into at least one cell type of each of at least two of the endodermal, ectodermal, and mesodermal lineages. The cells do not provoke a harmful immune response. The cells can modulate immune responses. As an example, the cells can suppress an immune response in a host engendered by allogeneic cells, tissues, and organs. Methods are described for using the cells, by themselves or adjunctively, to treat subjects. For instance, the cells can be used adjunctively for immunosuppression in transplant therapy. Methods for obtaining the cells and compositions for using them also are described.

First claim

What is claimed is:

1. A method of ameliorating an immune dysfunction in a subject; comprising administering to human subject mammalian multipotent adult progenitor cells characterized in that: they are not embryonic stem cells, embryonic germ cells, or germ cells, are allogeneic to the subject, express telomerase, have a normal karyotype, and have undergone at least 10-40 cell doublings in culture, wherein the cells are administered adjunctively to one or more other treatments wherein the cells have not been genetically engineered to improve their immunological properties, and wherein said immune dysfunction is not GVHD and is not diabetes.

2. A method according to claim 1 , wherein said progenitor cells can differentiate into cells of at least two of the endodermal, ectodermal, and mesodermal embryonic lineages.

3. A method according to claim 1 , wherein said progenitor cells are derived from cells isolated from any of placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, adipose tissue, and liver tissue.

4. A method according to claim 1 , wherein said progenitor cells are administered to said subject in one or more doses comprising 10 4 to 10 8 of said cells per kilogram of the subject's mass.

5. A method according to claim 4 , wherein said progenitor cells are administered to the subject in one or more doses comprising 10 6 to 10 7 of said progenitor cells per kilogram of the subject's mass.

6. A method according to claim 1 , wherein in addition to said progenitor cells, one or more growth factors, differentiation factors, signaling factors, and/or factors that increase homing are administered to said subject.

7. A method according to claim 1 , wherein further any combination of one or more of each of the following is administered to said subject: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

8. A method according to claim 1 , wherein said progenitor cells are administered in a formulation comprising one or more other pharmaceutically active agents.

9. A method according to claim 8 , wherein said formulation further comprises any combination of one or more of: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

10. A method according to claim 1 , wherein said progenitor cells are administered to the subject by a parenteral route.

11. A method according to claim 10 , wherein said progenitor cells are administered by intravenous infusion.

12. A method according to claim 2 , wherein said progenitor cells are derived from cells isolated from any of placental tissue, umbilical cord tissue, umbilical cord blood, bone marrow, blood, spleen tissue, thymus tissue, spinal cord tissue, adipose tissue, and liver tissue.

13. A method according to claim 2 , wherein said progenitor cells are administered to said subject in one or more doses comprising 10 4 to 10 8 of said cells per kilogram of the subject's mass.

14. A method according to claim 13 , wherein said progenitor cells are administered to the subject in one or more doses comprising 10 6 to 10 7 of said progenitor cells per kilogram of the subject's mass.

15. A method according to claim 2 , wherein in addition to said progenitor cells, one or more growth factors, differentiation factors, signaling factors, and/or factors that increase homing are administered to said subject.

16. A method according to claim 2 , wherein further any combination of one or more of each of the following is administered to said subject: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

17. A method according to claim 2 , wherein said progenitor cells are administered in a formulation comprising one or more other pharmaceutically active agents.

18. A method according to claim 2 , wherein said formulation further comprises any combination of one or more of: an antibiotic agent, an anti-fungal agent, and/or an anti-viral agent.

19. A method according to claim 2 , wherein said progenitor cells are administered to the subject by a parenteral route.

20. A method according to claim 2 , wherein said progenitor cells are administered by intravenous infusion.

21. A method according to any of claims 1 , 2 , 3 and 4 to 20 , where said cells are derived from bone marrow.

22. A method according to any of claims 1 , 2 , 3 and 4 to 20 , wherein said progenitor cells are human cells.

23. A method according to 22 , wherein said progenitor cells are derived from human bone marrow.

Assignees

• Abt Holding Co
• Univ Oregon Health & Science

Inventors

• Maziarz Richard
• Kovacsovics Magdalena
• Streeter Philip
• Deans Robert
• Van'T Hof Wouter

Classifications

• A61K39/00

  Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53) · CPC title

• A61K35/12 Primary

  Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells (vaccines or medicinal preparations containing antigens or antibodies A61K39/00) · CPC title

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61K45/06

  Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca · CPC title

• A61P37/06

  Immunosuppressants, e.g. drugs for graft rejection · CPC title